The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
https://www.mining.com/miners-now-saviours-in-green-transition/
https://xtractresources.com/wp-content/uploads/Bushranger-Summary-Presentation_April-2020.pdf
https://www.mining-technology.com/features/feature-top-ten-deepest-open-pit-mines-world/
What is the likelihood of an offer being made for HALO? Does it depend on Centrica selling Spirit Energy? Suitable buyer - Neptune?
Any idea when these will be revealed?
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has given Nuformix approval to commence its NXP001 human pharmacokinetics studies.
The drug, which is the company’s lead asset, will be evaluated in an open-label study to compare the bioavailability of it to Merck’s Emend in healthy subjects.
Nuformix is developing NXP001 as a treatment for chemotherapy-induced nausea and vomiting - a large, under-exploited and growing market, which in demographic terms comprises one third of global cancer patients.
The primary objective of the study is to investigate the pharmacokinetics and bioavailability of single oral doses of NXP001, and dosing will commence in March 2019, with results expected by the end of the first half of 2019.